New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

Completion of the screening pathway—not test selection alone—may define quality going forward.

Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.

Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.

Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.